In summary, we present strong evidence to support the idea that loss of function of VHL and TP53 is a bone fide tumour promoting combination and describe a mouse model that recapitulates many of the steps involved in the formation of VHL mutant kidney tumours in humans. The gene discussed is TP53; the disease is neoplasm.